258 related articles for article (PubMed ID: 34062782)
1. Microtubule-Associated Protein ATIP3, an Emerging Target for Personalized Medicine in Breast Cancer.
Haykal MM; Rodrigues-Ferreira S; Nahmias C
Cells; 2021 May; 10(5):. PubMed ID: 34062782
[TBL] [Abstract][Full Text] [Related]
2. Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy.
Rodrigues-Ferreira S; Nehlig A; Moindjie H; Monchecourt C; Seiler C; Marangoni E; Chateau-Joubert S; Dujaric ME; Servant N; Asselain B; de Cremoux P; Lacroix-Triki M; Arnedos M; Pierga JY; André F; Nahmias C
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23691-23697. PubMed ID: 31685623
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial expression of microtubule-associated EB1 and ATIP3 biomarkers improves breast cancer prognosis.
Rodrigues-Ferreira S; Nehlig A; Monchecourt C; Nasr S; Fuhrmann L; Lacroix-Triki M; Garberis I; Scott V; Delaloge S; Pistilli B; Vielh P; Dubois T; Vincent-Salomon A; André F; Nahmias C
Breast Cancer Res Treat; 2019 Feb; 173(3):573-583. PubMed ID: 30368744
[TBL] [Abstract][Full Text] [Related]
4. 8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis.
Rodrigues-Ferreira S; Di Tommaso A; Dimitrov A; Cazaubon S; Gruel N; Colasson H; Nicolas A; Chaverot N; Molinié V; Reyal F; Sigal-Zafrani B; Terris B; Delattre O; Radvanyi F; Perez F; Vincent-Salomon A; Nahmias C
PLoS One; 2009 Oct; 4(10):e7239. PubMed ID: 19794912
[TBL] [Abstract][Full Text] [Related]
5. ATIP3, a novel prognostic marker of breast cancer patient survival, limits cancer cell migration and slows metastatic progression by regulating microtubule dynamics.
Molina A; Velot L; Ghouinem L; Abdelkarim M; Bouchet BP; Luissint AC; Bouhlel I; Morel M; Sapharikas E; Di Tommaso A; Honoré S; Braguer D; Gruel N; Vincent-Salomon A; Delattre O; Sigal-Zafrani B; André F; Terris B; Akhmanova A; Di Benedetto M; Nahmias C; Rodrigues-Ferreira S
Cancer Res; 2013 May; 73(9):2905-15. PubMed ID: 23396587
[TBL] [Abstract][Full Text] [Related]
6. Microtubule-associated tumor suppressors as prognostic biomarkers in breast cancer.
Rodrigues-Ferreira S; Molina A; Nahmias C
Breast Cancer Res Treat; 2020 Jan; 179(2):267-273. PubMed ID: 31606824
[TBL] [Abstract][Full Text] [Related]
7. ATIP3 deficiency facilitates intracellular accumulation of paclitaxel to reduce cancer cell migration and lymph node metastasis in breast cancer patients.
Rodrigues-Ferreira S; Nehlig A; Kacem M; Nahmias C
Sci Rep; 2020 Aug; 10(1):13217. PubMed ID: 32764625
[TBL] [Abstract][Full Text] [Related]
8. Negative regulation of EB1 turnover at microtubule plus ends by interaction with microtubule-associated protein ATIP3.
Velot L; Molina A; Rodrigues-Ferreira S; Nehlig A; Bouchet BP; Morel M; Leconte L; Serre L; Arnal I; Braguer D; Savina A; Honore S; Nahmias C
Oncotarget; 2015 Dec; 6(41):43557-70. PubMed ID: 26498358
[TBL] [Abstract][Full Text] [Related]
9. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.
Murray S; Briasoulis E; Linardou H; Bafaloukos D; Papadimitriou C
Cancer Treat Rev; 2012 Nov; 38(7):890-903. PubMed ID: 22465195
[TBL] [Abstract][Full Text] [Related]
10. Predictive and Prognostic Value of the TauProtein in Breast Cancer.
Bonneau C; Gurard-Levin ZA; Andre F; Pusztai L; Rouzier R
Anticancer Res; 2015 Oct; 35(10):5179-84. PubMed ID: 26408675
[TBL] [Abstract][Full Text] [Related]
11. Predicting and Overcoming Taxane Chemoresistance.
Rodrigues-Ferreira S; Moindjie H; Haykal MM; Nahmias C
Trends Mol Med; 2021 Feb; 27(2):138-151. PubMed ID: 33046406
[TBL] [Abstract][Full Text] [Related]
12. Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer.
Lumachi F; Chiara GB; Foltran L; Basso SM
Cancer Genomics Proteomics; 2015; 12(6):385-90. PubMed ID: 26543084
[TBL] [Abstract][Full Text] [Related]
13. [Biomarker].
Ueno T; Toi M
Gan To Kagaku Ryoho; 2009 Jan; 36(1):15-20. PubMed ID: 19151560
[TBL] [Abstract][Full Text] [Related]
14. From tumorigenesis to cell death: the aneuploidy paradox.
Rodrigues-Ferreira S; Nahmias C
Mol Cell Oncol; 2020; 7(2):1709390. PubMed ID: 32158924
[TBL] [Abstract][Full Text] [Related]
15. Predictive biomarkers for personalized medicine in breast cancer.
Rodrigues-Ferreira S; Nahmias C
Cancer Lett; 2022 Oct; 545():215828. PubMed ID: 35853538
[TBL] [Abstract][Full Text] [Related]
16. LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer.
Lovat F; Ishii H; Schiappacassi M; Fassan M; Barbareschi M; Galligioni E; Gasparini P; Baldassarre G; Croce CM; Vecchione A
Oncotarget; 2014 Feb; 5(4):970-7. PubMed ID: 24448468
[TBL] [Abstract][Full Text] [Related]
17. A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate.
Akbulut O; Lengerli D; Saatci O; Duman E; Seker UOS; Isik A; Akyol A; Caliskan B; Banoglu E; Sahin O
Mol Cancer Ther; 2020 Jun; 19(6):1243-1254. PubMed ID: 32217742
[TBL] [Abstract][Full Text] [Related]
18. The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers.
Légaré S; Cavallone L; Mamo A; Chabot C; Sirois I; Magliocco A; Klimowicz A; Tonin PN; Buchanan M; Keilty D; Hassan S; Laperrière D; Mader S; Aleynikova O; Basik M
Cancer Res; 2015 Oct; 75(20):4351-63. PubMed ID: 26297734
[TBL] [Abstract][Full Text] [Related]
19. Precision Medicine and Targeted Therapies in Breast Cancer.
Greenwalt I; Zaza N; Das S; Li BD
Surg Oncol Clin N Am; 2020 Jan; 29(1):51-62. PubMed ID: 31757313
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts.
Baquero MT; Lostritto K; Gustavson MD; Bassi KA; Appia F; Camp RL; Molinaro AM; Harris LN; Rimm DL
Breast Cancer Res; 2011 Nov; 13(5):R85. PubMed ID: 21888627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
